SYS-CON MEDIA Authors: Elizabeth White, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Cytovance Biologics Selected for GMP Manufacture of AM0010 for ARMO BioSciences

OKLAHOMA CITY, OK -- (Marketwired) -- 06/23/14 -- Cytovance Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, announces successful completion of GMP manufacture of ARMO BioSciences' lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10).

"Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product," states Darren Head, President and Chief Executive Officer of Cytovance Biologics. "Our team responded to the urgency to get this important drug to patients with advanced solid tumors."

"Cytovance's responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase 1 dose escalation study in patients with cancer," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO. "We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010."

"Cytovance's state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for ARMO," adds Darren Head. "We are delighted to work with ARMO. Their fast pace and rigorous scientific know-how are a good match for Cytovance's sense of urgency and flexibility. Together, we can produce high quality material for patients quickly and efficiently in a cost-efficient manner."

About ARMO BioSciences, Inc.

ARMO BioSciences, a clinical stage biotechnology company based in Redwood City, CA is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases. ARMO's medicines are designed to normalize the underlying biology of disease through immunotherapeutic mechanisms for sustained and durable responses. Founded in 2012, ARMO is backed by investors Kleiner Perkins Caufield & Byers, OrbiMed, DAG Ventures and NanoDimension.

Further information regarding ARMO BioSciences, Inc. is available at www.armobio.com.

About Cytovance® Biologics

Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.

Learn more about Cytovance Biologics at www.cytovance.com.

Media Contact
Jodie Gutkowski
Marketing/Communications Manager
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.